Ivonescimab for advanced thymic carcinoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called ivonescimab for thymic carcinoma that has come back or isn't responding to other treatments. It aims to see if this drug can shrink the cancer and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a type of thymus cancer called thymic carcinoma.
- Your cancer must have been treated before, or you must not be able to have standard treatments.
- You need to be able to do your daily activities (like walking and self-care) mostly on your own (ECOG score 0 or 1).
- Your kidneys, liver, and blood counts must be working well enough, shown by blood and urine tests.
- You cannot have had any prior treatment with a PD-1 or PD-L1 checkpoint inhibitor (like Keytruda or Opdivo).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an immunotherapy drug (ivonescimab) plus chemotherapy as the first treatment for people with advanced or recurrent thymic cancer. The goal is to see how well this combination works and how safe it is.
This study tests a new immunotherapy drug called ivonescimab given before surgery for people with advanced head and neck cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
This study tests a new drug called ivonescimab for people with advanced endometrial or cervical cancer that has progressed after standard platinum-based chemotherapy. Ivonescimab is an investigational immunotherapy that may help your immune system fight the cancer.
This trial tests a new drug (ivonescimab) combined with a procedure that uses heat to destroy tumors (radiofrequency ablation) for people with advanced cancer that has not responded to prior immunotherapy. The goal is to see if this combination can help control the cancer when other treatments have stopped working.
This study tests a new drug called ivonescimab for people with advanced adrenal gland tumors (adrenocortical carcinoma or pheochromocytoma/paraganglioma) that have spread and can't be removed with surgery. The goal is to see if the drug can shrink or slow the growth of the tumors.
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Hear when a new Thymus Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.